T. Rowe Price Associates
EWTX icon

T. Rowe Price Associates’s Edgewise Therapeutics EWTX Stock Holding History

T. Rowe Price Associates’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.2M Buy
816,518
+747,091
+1,076% +$25.8M ﹤0.01% 1004
2026
Q1 		$2.19M Buy
69,427
+12,112
+21% +$349K ﹤0.01% 1790
2025
Q4 		$1.42M Buy
57,315
+5,929
+12% +$119K ﹤0.01% 1918
2025
Q3 		$834K Buy
51,386
+704
+1% +$9.98K ﹤0.01% 2141
2025
Q2 		$665K Sell
50,682
-244,199
-83% -$3.52M ﹤0.01% 2167
2025
Q1 		$6.49M Buy
294,881
+265,831
+915% +$6.97M ﹤0.01% 1201
2024
Q4 		$776K Buy
29,050
+5,242
+22% +$167K ﹤0.01% 2081
2024
Q3 		$636K Buy
23,808
+722
+3% +$14.4K ﹤0.01% 2163
2024
Q2 		$416K Buy
23,086
+6,662
+41% +$116K ﹤0.01% 2265
2024
Q1 		$300K Sell
16,424
-109,647
-87% -$1.74M ﹤0.01% 2434
2023
Q4 		$1.38M Buy
126,071
+367
+0.3% +$2.58K ﹤0.01% 1713
2023
Q3 		$722K Buy
125,704
+1,024
+0.8% +$6.96K ﹤0.01% 1947
2023
Q2 		$968K Buy
124,680
+2,110
+2% +$17.8K ﹤0.01% 1827
2023
Q1 		$819K Sell
122,570
-135,756
-53% -$1.26M ﹤0.01% 1883
2022
Q4 		$2.31M Buy
258,326
+2,088
+0.8% +$19.6K ﹤0.01% 1418
2022
Q3 		$2.52M Sell
256,238
-92,985
-27% -$940K ﹤0.01% 1371
2022
Q2 		$2.78M Sell
349,223
-552
-0.2% -$4.17K ﹤0.01% 1527
2022
Q1 		$3.39M Buy
+349,775
New +$4.5M ﹤0.01% 1545

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's EWTX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Edgewise Therapeutics (EWTX) stake by 1,076% in Q2 2026, buying an estimated $25.8M and bringing the position to 816,518 shares worth $33.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1004.

T. Rowe Price Associates first reported a position in EWTX in Q1 2022 and has held it in 18 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • T. Rowe Price Associates held 816,518 shares of Edgewise Therapeutics worth $33.2M as of Q2 2026.
  • T. Rowe Price Associates bought 747,091 Edgewise Therapeutics shares in Q2 2026, an estimated $25.8M.
  • Edgewise Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1004 holding.
  • T. Rowe Price Associates first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.